









Markets
/
Stocks
/
nasdaq-tgtx
/

TG Therapeutics Inc

TGTX



View Detailed Chart

31.070USD

+0.340+1.11%

Close 12/24, 16:00（ET）Quotes delayed by 15 min

4.82BMarket Cap

10.15P/E TTM



TG Therapeutics Inc

31.070

+0.340+1.11%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+1.11%

5 Days

+3.81%

1 Month

-5.79%

6 Months

-16.61%

Year to Date

+3.22%

1 Year

-3.39%

View Detailed Chart

TradingKey Stock Score of TG Therapeutics Inc

Currency: USD Updated: 2025-12-24

Key Insights

TG Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 80/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 44.29.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

TG Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

80 / 158

Overall Ranking

201 / 4562

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

44.286

Target Price

+43.64%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

TG Therapeutics Inc Highlights

StrengthsRisks

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 11713.43% year-on-year.

Fairly Valued

The company’s latest PE is 10.15, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 101.46M shares, decreasing 14.52% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 979.27K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.19.